一品红：子公司获得己酮可可碱缓释片注册证书

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for its subsidiary Guangzhou Lianrui Pharmaceutical Co., Ltd. to market Ketone Cocoa Alkaloid Sustained-Release Tablets, which are indicated for peripheral vascular diseases, including intermittent claudication and rest pain [1] Group 1: Product Approval - The approval includes a drug registration certificate for Ketone Cocoa Alkaloid Sustained-Release Tablets [1] - The tablets are designed to improve blood rheological properties by reducing blood viscosity, thereby enhancing blood flow in patients with chronic peripheral artery disease [1] Group 2: Mechanism of Action - Ketone Cocoa Alkaloid and its metabolites improve blood rheological characteristics in a dose-dependent manner [1] - The exact mechanism of action remains unclear, but it is known to enhance red blood cell deformability and improve leukocyte deformability while inhibiting neutrophil adhesion and activation [1]